iShares U.S. Pharmaceuticals ETF logo

iShares U.S. Pharmaceuticals ETF (IHE)

Market Closed
16 Oct, 08:00 PM
ARCA ARCA
$
101. 06
-0.06
-0.0593%
$
1.13B Market Cap
1.18% Div Yield
458,750 Volume
$ 101.12
Previous Close
Add Transaction
Day Range
100.79 101.85
Year Range
73.42 108.66
Want to track IHE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.

Zacks | 1 year ago
IHE Contraction Is Not Justified By Fundamental Data

IHE Contraction Is Not Justified By Fundamental Data

iShares U.S. Pharmaceuticals ETF is a pharmaceutical ETF offered by iShares, featuring an expense ratio of 0.39% and over $500 million in assets under management. In Q3, the healthcare sector reported earnings that exceeded expectations (+9.3%) and provided strong guidance for CV 2025, according to FactSet. The IHE prices are down 10% from their all-time high, with the next point of control 20% lower, while the maximum drawdown in the past 10 years was 40%.

Seekingalpha | 1 year ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.

Zacks | 1 year ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Zacks | 2 years ago
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)

IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)

IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently. Despite being a defensive play in an economic recession, IHE can still experience significant declines due to market sentiment.

Seekingalpha | 2 years ago
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.

Zacks | 2 years ago